CpG Still Rocks! Update on an Accidental Drug

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nucleic Acid Therapeutics

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/nat.2012.0340PMID 22352814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccination‐induced functional competence of circulating human tumor‐specific CD8 T‐cells

  2012cited by this paper
• CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

  2012cited by this paper
• Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages

  2011cited by this paper
• Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.

  2011cited by this paper
• Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice

  2011cited by this paper
• Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

  2011cited by this paper
• TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.

  2011cited by this paper
• Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

  2011cited by this paper
• Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

  2011cited by this paper
• Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

  2011cited by this paper
• Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

  2011influential reference
• Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

  2011influential reference
• Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

  2010cited by this paper
• Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

  2010cited by this paper
• BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

  2010cited by this paper
• Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

  2010cited by this paper
• Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.

  2010cited by this paper
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

  2010cited by this paper
• Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

  2010influential reference
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.

  2010cited by this paper
• Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

  2010cited by this paper
• Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

  2010cited by this paper
• A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

  2009cited by this paper
• CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.

  2009cited by this paper
• Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.

  2009cited by this paper
• Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

  2009cited by this paper
• Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.

  2009cited by this paper
• Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

  2009cited by this paper
• The TLR9 Ligand CpG Promotes the Acquisition of Plasmodium falciparum-Specific Memory B Cells in Malaria-Naive Individuals1

  2009cited by this paper
• Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial

  2009cited by this paper
• PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1

  2009cited by this paper
• Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

  2009cited by this paper
• Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

  2009cited by this paper
• A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

  2009influential reference
• Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

  2008cited by this paper
• Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

  2008cited by this paper
• Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

  2008cited by this paper
• Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

  2008cited by this paper
• The coming of age of virus-like particle vaccines

  2008cited by this paper
• Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft

  2008cited by this paper
• Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

  2008cited by this paper
• Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

  2007cited by this paper
• Antiinfective applications of toll-like receptor 9 agonists.

  2007cited by this paper
• Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

  2007influential reference
• Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients

  2007cited by this paper
• Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1

  2007cited by this paper
• Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity

  2007cited by this paper
• CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.

  2007cited by this paper
• Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist

  2007cited by this paper
• GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

  2007cited by this paper
• Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

  2007cited by this paper
• Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis

  2007cited by this paper
• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

  2006cited by this paper
• Decreased specific CD8+ T cell cross‐reactivity of antigen recognition following vaccination with Melan‐A peptide

  2006cited by this paper
• Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

  2006cited by this paper
• New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1

  2006cited by this paper
• Therapeutic potential of Toll-like receptor 9 activation

  2006cited by this paper
• A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination1

  2006cited by this paper
• Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.

  2006cited by this paper
• Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.

  2006cited by this paper
• Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.

  2006cited by this paper
• Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

  2006cited by this paper
• Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma

  2006influential reference
• CXCL16 Influences the Nature and Specificity of CpG-Induced Immune Activation12

  2006cited by this paper
• G3139 and Other CpG-Containing Immunostimulatory Phosphorothioate Oligodeoxynucleotides Are Potent Suppressors of the Growth of Human Tumor Xenografts in Nude Mice

  2006cited by this paper
• CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.

  2006cited by this paper
• CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults

  2005cited by this paper
• HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.

  2005cited by this paper
• Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.

  2005cited by this paper
• Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

  2005cited by this paper
• Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction

  2005cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.

  2004cited by this paper
• Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist

  2004cited by this paper
• Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

  2004cited by this paper
• CpG-C Immunostimulatory Oligodeoxyribonucleotide Activation of Plasmacytoid Dendritic Cells in Rhesus Macaques to Augment the Activation of IFN-γ-Secreting Simian Immunodeficiency Virus-Specific T Cells1

  2004cited by this paper
• Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

  2004cited by this paper
• Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

  2004cited by this paper
• CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

  2004cited by this paper
• Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

  2004cited by this paper
• Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.

  2004cited by this paper
• A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

  2003cited by this paper
• Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells

  2003cited by this paper
• CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice

  2003cited by this paper
• CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.

  2003cited by this paper
• Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

  2003cited by this paper
• CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both?

  2003cited by this paper
• CpG motifs in bacterial DNA and their immune effects.

  2002influential reference
• Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.

  2001cited by this paper
• Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

  2000cited by this paper
• A Toll-like receptor recognizes bacterial DNA

  2000cited by this paper
• Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.

  2000cited by this paper
• Conjugation of protein to immunostimulatory DNA results in a rapid, long‐lasting and potent induction of cell‐mediated and humoral immunity

  2000cited by this paper
• Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma.

  1998cited by this paper
• CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry.

  1998cited by this paper
• CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

  1998cited by this paper

• Introduction to the Immune System.

  2026cites this paper
• Advancing ICOS agonism in solid tumors: lessons from INDUCE-1

  2026cites this paper
• A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E.

  2025cites this paper
• Clinical Applications of Oligonucleotides for Cancer Therapy.

  2025cites this paper
• Differential innate immune activation by four different CpG-ODNs in porcine and murine cells: Implications for vaccine design.

  2025cites this paper
• Cell-selective telomere damage by thiopurine-based oligonucleotide for diffuse large B cell lymphoma immunotherapy

  2025cites this paper
• Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

  2025cites this paper
• Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines

  2024cites this paper
• Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors

  2024cites this paper
• Perioperative hypothermia and stress jeopardize antimetastatic immunity and TLR-9 immune activation: potential mediating mechanisms (experimental studies)

  2024cites this paper
• Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA

  2024cites this paper
• Schlafen-11 and -9 are innate immune sensors for intracellular single-stranded DNA

  2024cites this paper
• Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids

  2024cites this paper
• Evaluation of the Performance of a New Pentavalent Vaccine in Poultry

  2024cites this paper
• Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.

  2023cites this paper
• Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors

  2023cites this paper
• Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies

  2023cites this paper
• Photothermal Induced Chemo-immunological Synergistic Therapy for Anaplastic Thyroid Carcinoma Treatment

  2023cites this paper
• Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer

  2023cites this paper
• Nanoparticle-Conjugated TLR9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines

  2023cites this paper
• Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

  2022cites this paper
• Cutaneous CpG adjuvant conditioning to enhance vaccine responses.

  2022cites this paper
• DNA Damage Repair in Brain Tumor Immunotherapy

  2022cites this paper
• AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets

  2022cites this paper
• Vaccine adjuvants to engage the cross-presentation pathway

  2022cites this paper
• Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs

  2022cites this paper
• A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

  2022cites this paper
• G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects

  2022cites this paper
• Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions.

  2022cites this paper
• Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

  2021cites this paper
• Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

  2021cites this paper
• Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.

  2021influential citation
• The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy

  2021cites this paper
• Generation of αCD11b-CpG antibody conjugates for the targeted stimulation of myeloid cells.

  2021cites this paper
• Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

  2021cites this paper
• Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy

  2021cites this paper
• From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.

  2021cites this paper
• Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

  2021influential citation
• CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats

  2021cites this paper
• TLR Ligand Loaded Exosome Mediated Immunotherapy of Established Mammary Tumor In Mice.

  2021cites this paper
• Elucidating the Motif for CpG Oligonucleotide Binding to the Dendritic Cell Receptor DEC-205 Leads to Improved Adjuvants for Liver-Resident Memory

  2021cites this paper
• Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles

  2021cites this paper
• Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness

  2020cites this paper
• A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo

  2020influential citation
• Adjuvant-free immunization with infective filarial larvae as lymphatic homing antigen carriers

  2020cites this paper
• Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization

  2020cites this paper
• Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.

  2020cites this paper
• Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.

  2020cites this paper
• Synthesis and properties of DNA oligomers containing stereopure phosphorothioate linkages and C-5 modified deoxyuridine derivatives

  2020cites this paper
• Dual-adjuvant effect of PH-sensitive liposomes loaded with sting and TLR9 agonists regress tumor development by enhancing TH1 immune response.

  2020cites this paper
• Chemical Strategies to Boost Cancer Vaccines.

  2020cites this paper
• CpG-Oligodeoxynucleotides Alleviate Tert-Butyl Hydroperoxide-Induced Macrophage Apoptosis by Regulating Mitochondrial Function and Suppressing ROS Production

  2020cites this paper
• Low molecular weight chitosan nanoparticles for CpG oligodeoxynucleotides delivery: Impact of molecular weight, degree of deacetylation, and mannosylation on intracellular uptake and cytokine induction.

  2020cites this paper
• Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

  2020cites this paper
• The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus‐Like Particles

  2020cites this paper
• Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis)

  2020influential citation
• Harnessing cancer immunotherapy during the unexploited immediate perioperative period

  2020cites this paper
• Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases

  2019cites this paper
• Therapeutic Oligonucleotides: State of the Art.

  2019cites this paper
• A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.

  2019cites this paper
• Caractérisation non-biaisée de l'hétérogénéité des macrophages interstitiels pulmonaires murins et mise en évidence de précurseurs monocytaires locaux

  2019cites this paper
• Future horizons in Alzheimer's disease research.

  2019cites this paper
• The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy

  2019cites this paper
• Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates

  2019cites this paper
• Introduction to the Immune System.

  2019cites this paper
• Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial

  2019cites this paper
• The versatile plasmacytoid dendritic cell: Function, heterogeneity, and plasticity.

  2019cites this paper
• Deleterious synergistic effects of distress and surgery on cancer metastasis: Abolishment through an integrated perioperative immune-stimulating stress-inflammatory-reducing intervention.

  2019cites this paper
• NMR solution structure of tricyclo-DNA containing duplexes: insight into enhanced thermal stability and nuclease resistance

  2019cites this paper
• Cell‐surface‐bound circulating DNA in the blood: Biology and clinical application

  2019cites this paper
• Effect of a DNA-based immunostimulant on growth, performance, and expression of inflammatory and immune mediators in beef calves abruptly weaned and introduced to a complete ration.

  2018cites this paper
• Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections

  2018cites this paper
• Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.

  2018cites this paper
• Irreversible Electroporation in Clinical Practice

  2018cites this paper
• NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases

  2018cites this paper
• Lung Interstitial Macrophages: Past, Present, and Future

  2018cites this paper
• B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors

  2018cites this paper
• Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease

  2018cites this paper
• Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation

  2018cites this paper
• IFN‐γ stimulates CpG‐induced IL‐10 production in B cells via p38 and JNK signalling pathways

  2018cites this paper
• Molecular Basis of Resilience

  2018cites this paper
• Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4+ T Cell-Independent CD8+ T-Cell Response Against Unconjugated Protein Antigen

  2018cites this paper
• STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers

  2018cites this paper
• Natural antisense transcripts in diseases: From modes of action to targeted therapies

  2018cites this paper
• Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice

  2018cites this paper
• Changes of KEAP1/NRF2 and IKB/NF-κB Expression Levels Induced by Cell-Free DNA in Different Cell Types

  2018cites this paper
• Doctoral Dissertation(Shinshu University) A Study on the immune effects of synergistic oligodeoxynucleotide from probiotics

  2018cites this paper
• The revival of CpG oligonucleotide-based cancer immunotherapies

  2018cites this paper
• Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge

  2018cites this paper
• From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation

  2018cites this paper
• The Medicinal Chemistry of Antisense Oligonucleotides

  2018cites this paper
• The effects of vitamin A in B cells from patients with the immunodeficiency disorder CVID

  2018influential citation
• Manufacturing of Oligonucleotides

  2017cites this paper
• Administration de médicament médiée par un récepteur fc

  2017cites this paper
• CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses

  2017cites this paper
• Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities

  2017cites this paper
• Biomaterials for polynucleotide delivery to anchorage-independent cells.

  2017cites this paper
• Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant

  2017cites this paper
• Using dendritic cell receptors to enhance immunity

  2017influential citation
• Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

  2017influential citation